New Releases from NCBI BookshelfOdevixibat for treating progressive familial intrahepatic cholestasis .Odevixibat for treating progressive familial intrahepatic cholestasis .
Post Content
Uncategorized
Uncategorized
New Releases from NCBI BookshelfCo-designing and testing the learn together guidance to support patient and family involvement in patient safety investigations: a mixed-methods study.Co-designing and testing the learn together guidance to support patient and family involvement in patient safety investigations: a mixed-methods study.
There are multiple reasons for involving patients and families in incident investigations. Fiscally, costs due to clinical negligence claims approximate
Uncategorized
New Releases from NCBI BookshelfSelumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.
Post Content
Uncategorized
New Releases from NCBI BookshelfWHO recommendations on maternal health: guidelines approved by the WHO Guidelines Review Committee [Internet].WHO recommendations on maternal health: guidelines approved by the WHO Guidelines Review Committee [Internet].
This publication on WHO recommendations related to maternal health is one of four in a series; the others relate to
Uncategorized
New Releases from NCBI BookshelfBehaviour change interventions to promote physical activity in people with intermittent claudication: the OPTIMA systematic review.Behaviour change interventions to promote physical activity in people with intermittent claudication: the OPTIMA systematic review.
People with intermittent claudication are significantly less active compared to their peers without intermittent claudication, worsening future health outcomes. Supervised
Uncategorized
New Releases from NCBI BookshelfIvacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation.Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation.
Cystic fibrosis is a life-limiting genetic condition that affects over 9000 people in England. Cystic fibrosis is usually diagnosed through